Modeling Study of Phenylsulfonylfuroxan Derivatives as P-gp Inhibitors: A Combined Approach of CoMFA, CoMSIA and HQSAR

By  

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 14, Iss. 7, 2014-09 ,pp. : 1019-1030

Bentham Science Publishers

Access to resources Recommend Favorite

EGFR/HER2 inhibitors effectively reduce the malignant potential of MDR breast cancer evoked by P-gp substrates in vitro and in vivo

By              

Oncology Reports, Vol. 35, Iss. 2, 2016-01 ,pp. : 771-778

Spandidos Publications

Access to resources Recommend Favorite

Modulation of P-Glycoprotein (PGP) Mediated Multidrug Resistance (MDR) Using Chemosensitizers: Recent Advances in the Design of Selective MDR Modulators

By  

Current Medicinal Chemistry - Anti-Cancer Agents, Vol. 1, Iss. 2, 2001-08 ,pp. : 163-174

Bentham Science Publishers

Access to resources Recommend Favorite

Recent Advances in Hsp90 Inhibitors as Antitumor Agents

By  

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 8, Iss. 7, 2008-10 ,pp. : 761-782

Bentham Science Publishers

Access to resources Recommend Favorite

Advances in Development of Inhibitors of 17&bgr;-Hydroxysteroid Dehydrogenases

By  

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 9, Iss. 6, 2009-01 ,pp. : 642-660

Bentham Science Publishers

Access to resources Recommend Favorite